ArticleBiomaterials2016
Synthetic virus-like particles prepared via protein corona formation enable effective vaccination in an avian model of coronavirus infection.
Article in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 90 citations in OpenAlex.
- Nanoparticle-Based Antiviral Vaccines for Chickens: Recent Advances and Future Perspectives.Transboundary and emerging diseases · 2025Review
- Review
- Aptamer-decorated nanocarriers for viral adsorption: A special look at COVID-19.Molecular therapy. Nucleic acids · 2024Review
- Article
- Article
- SARS-CoV-2 Virus-like Particles with Plasmonic Au Cores and S1-Spike Protein Coronas.ACS synthetic biology · 2023Article
- Review
- Superior possibilities and upcoming horizons for nanoscience in COVID-19: noteworthy approach for effective diagnostics and management of SARS-CoV-2 outbreak.Chemicke zvesti · 2023Review
- Immunomodulatory nanosystems: An emerging strategy to combat viral infections.Biomaterials and biosystems · 2023Review
- SARS-CoV-2 and its new variants: a comprehensive review on nanotechnological application insights into potential approaches.Applied nanoscience · 2023Review
- Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19.Plasmonics (Norwell, Mass.) · 2023Review
- Applications of Gold and Silver Nanoparticles in Theranostics.Applied biochemistry and biotechnology · 2022Review
- Nanotechnology-facilitated vaccine development during the coronavirus disease 2019 (COVID-19) pandemic.Exploration (Beijing, China) · 2022Review
- SARS-CoV-2 and influenza viruses: Strategies to cope with coinfection and bioinformatics perspective.Cell biology international · 2022Review
- Efficacy and Immune Response Elicited by Gold Nanoparticle- Based Nanovaccines against Infectious Diseases.Vaccines · 2022Review
- Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients.Journal of drug delivery science and technology · 2022Review
- The quest for a better fight: How can nanomaterials address the current therapeutic and diagnostic obstacles in the fight against COVID-19?Journal of drug delivery science and technology · 2022Review
- Novel and Alternative Therapeutic Strategies for Controlling Avian Viral Infectious Diseases: Focus on Infectious Bronchitis and Avian Influenza.Frontiers in veterinary science · 2022Review
- Nanotechnology: A Potential Weapon to Fight against COVID-19.Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems · 2022Review
- Metal Nanoparticles against Viruses: Possibilities to Fight SARS-CoV-2.Nanomaterials (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ongoing battle against current and rising viral infectious threats has prompted increasing effort in the development of vaccine technology. A major thrust in vaccine research focuses on developing formulations with virus-like features towards enhancing antigen presentation and immune processing. Herein, a facile approach to formulate synthetic virus-like particles (sVLPs) is demonstrated by exploiting the phenomenon of protein corona formation induced by the high-energy surfaces of synthetic nanoparticles. Using an avian coronavirus spike protein as a model antigen, sVLPs were prepared by incubating 100 nm gold nanoparticles in a solution containing an optimized concentration of viral proteins. Following removal of free proteins, antigen-laden particles were recovered and showed morphological semblance to natural viral particles under nanoparticle tracking analysis and transmission electron microscopy. As compared to inoculation with free proteins, vaccination with the sVLPs showed enhanced lymphatic antigen delivery, stronger antibody titers, increased splenic T-cell response, and reduced infection-associated symptoms in an avian model of coronavirus infection. Comparison to a commercial whole inactivated virus vaccine also showed evidence of superior antiviral protection by the sVLPs. The study demonstrates a simple yet robust method in bridging viral antigens with synthetic nanoparticles for improved vaccine application; it has practical implications in the management of human viral infections as well as in animal agriculture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.